Joseph Mungari, DPM
Podiatrist · New Hartford, NYNPI 1235153164
Payments from drug & device makers
Across 38 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Treace Medical Concepts, Inc.$506
- Paratek Pharmaceuticals, Inc.$97
- Amgen$44
- Nabriva Therapeutics, PLC$34
- Smith+Nephew$30
- Zyla Life Sciences, Inc.$22
- plus $50 from 4 others
What the payments were for
- Food & beverage$783100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Treace Medical Concepts, Inc. | 20 | $506 |
| Paratek Pharmaceuticals, Inc. | 7 | $97 |
| Amgen | 3 | $44 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Smith+Nephew | 1 | $30 |
| Zyla Life Sciences, Inc. | 1 | $22 |
| Advanced Oxygen Therapy Inc. | 1 | $14 |
| Bioventus LLC | 1 | $13 |
| Merck | 1 | $11 |
| Assertio Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$783 in reported general payments places this provider in the 55th percentile of 862 podiatrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 25 | $1,264 |
| Ammonium Lactate | 34 | $1,042 |
| Diclofenac Sodium | 26 | $582 |
| SsdSilver Sulfadiazine | 28 | $357 |
| Mupirocin | 16 | $238 |
| Ketorolac Tromethamine | 11 | $157 |
| Cephalexin | 21 | $125 |
| Silver Sulfadiazine | 14 | $125 |
| Meloxicam | 23 | $44 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in New Hartford
- Christopher BromleyPoughkeepsie$152K
- Scott GawlikBrooklyn$77K
- Waldemar MajdanskiAstoria$71K
- Michael HutzelSeaford$64K
- Donald RubinCorning$53K
- Steven NormanMiddle Village$42K
- Elvis DanneNew York$35K
- Adam CirlincioneGlen Cove$31K
- Jude ViolanteNiagara Falls$30K
- Ammar Al RubaiayNew Hyde Park$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.